Delivery Order SPE2DB24D1021-SPE2DB25FFAGB
- Not listed
- The Defense Logistics Agency awarded a $7,022.45 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-competitive delivery order is issued under a firm fixed-price arrangement and represents a single pharmaceutical supply transaction sourced from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. HUMIRA is a widely prescribed biologic immunosuppressant used to...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL doses. This is a firm fixed price delivery order with no set-aside designation, demonstrating that the award was competitively procured. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. HUMIRA is a widely...
- The Defense Logistics Agency awarded a delivery order valued at $5,497.68 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL on August 19, 2025, with completion targeted for August 20, 2025. This firm fixed-price delivery order represents a non-set-aside competitive procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic immunosuppressant medication prescribed for various autoimmune conditions including...
- The Defense Logistics Agency awarded a $4,531.80 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The place of...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,192.80 for HUMIRA Pen 40 mg/0.8 mL on August 15, 2025, with an ultimate completion date of August 18, 2025. This non-set-aside, firm fixed price delivery order was issued under a competitive procurement process and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic immunosuppressant medication commonly prescribed for rheumatologic...
- The Defense Logistics Agency awarded a delivery order valued at $9,883.59 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 21, 2025, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered from...
- The Defense Logistics Agency awarded a $2,265.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 28, 2025, with an ultimate completion date of August 29, 2025. This non-set-aside contract represents a pharmaceutical supply delivery under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery location is...
- The Defense Logistics Agency has awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA Pen 40 mg/0.8 mL units. This competitively awarded, firm fixed price contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic medication for treating autoimmune conditions including rheumatoid arthritis,...
- The Defense Logistics Agency awarded a $19,774.30 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a ceiling value of $999,999,999.00 through December 2026. The performance location is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $5,857.24 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FFAGBDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,265.90 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mls on September 4, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price delivery order was placed with no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HUMIRA (adalimumab) is a widely-used biologic immunosuppressant medication indicated for autoimmune and inflammatory conditions including rheumatoid arthritis, psoriasis, and Crohn's disease. This delivery order is executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 potential value and runs through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen supplies comprehensive medical commodities to support military healthcare programs globally through the DLA Medical Supply Chain, serving customers including the Defense Health Agency and U.S. Coast Guard. The parent IDC functions as a flexible contracting vehicle enabling AmerisourceBergen to deliver pharmaceutical products, medical supplies, specialty medications, vaccines, and related healthcare commodities across multiple therapeutic domains to support federal medical procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 9/4/25 |